Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKW-08
- Development stage
- Preclinical
- Lead developer
- Skye Biologics
- Administration
- Local Injection
01
Overview
SKW-08 is a biological therapeutic candidate developed by Skye Biologics for the treatment of plantar fasciitis. It is part of the company's "2nd Generation" pipeline of regenerative medicine products, which utilize naturally advanced human biological materials to facilitate tissue repair and healing. The therapy is specifically designed for musculoskeletal applications within the foot and ankle, aiming to promote the repair of damaged plantar fascia tissue. While the specific biological source and molecular targets are not publicly disclosed, the product leverages the innate healing properties of human-derived biologics to address chronic inflammation and tissue degeneration.
Beyond the preview
Go deeper on SKW-08.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKW-08.